All relevant data are available in the Supporting Information files and in the Gene Expression Omnibus GSE16011 dataset (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011>).

Introduction {#sec005}
============

Glioblastoma multiform (GBM) is the most common malignant primary brain tumor, accounting for 15.6% of all primary brain tumors and 45.2% of primary malignant brain tumors\[[@pone.0151815.ref001]\]. The 5-year survival rate of GBM patients is less than 5% \[[@pone.0151815.ref002]\]. Such suboptimal efficacy in primary GBM management is partially attributed to the highly invasive nature of glioma cells, which are capable of diffusely infiltrating and widely migrating into the surrounding brain tissue\[[@pone.0151815.ref003]\]. Furthermore, invasive tumor cells can escape surgical removal and are relatively resistant to radiation therapy and chemotherapy\[[@pone.0151815.ref004]\]. Due to the unsatisfactory efficacy of the current treatments for primary GBM, there is an unmet medical need for clinical biomarkers that can predict patient survival and response to treatment.

Recent studies focusing on the mechanisms of glioma invasion suggested a role of matrix metalloproteinases (MMPs) in the process of glioma cell invasion \[[@pone.0151815.ref003]\]. MMPs, a family of zinc-dependent endopeptidases\[[@pone.0151815.ref005]\], regulate tumor invasion and metastasis through their extracellular matrix (ECM) degradation capacity in the extracellular milieu of various tissues\[[@pone.0151815.ref006]--[@pone.0151815.ref010]\]. Although MMP expression levels are highly variable from one tumor to another\[[@pone.0151815.ref011], [@pone.0151815.ref012]\], their increased expression suggests a close association with malignant progression of various human cancers\[[@pone.0151815.ref013]--[@pone.0151815.ref016]\]. Mounting evidence has demonstrated that increased MMPs expression is related to poor prognosis in the majority of human tumors, including glioma\[[@pone.0151815.ref017]--[@pone.0151815.ref021]\]. Many studies have confirmed the association between the expression of *MMP1*, *2*, *7*, *9*, *11*, *12*, *14*, *15*, *25* and the tumor grade, whereas that *MMP3*, *8*, *10*, *13*, *16*, *17*, *20*, *21*, *23*, *26*, *27* and *28* do not seem to play a major role in glioblastoma development\[[@pone.0151815.ref022]--[@pone.0151815.ref028]\]. The available data for *MMP19* and *24* are contradictory, as some studies suggest their involvement during the development of astrocytic tumors\[[@pone.0151815.ref012], [@pone.0151815.ref029]\], and while others do not\[[@pone.0151815.ref030]\].

In the present study, we comparatively analyzed the MMP family members based on whole-gene expression profiling from multiple databases ([Table 1](#pone.0151815.t001){ref-type="table"}), and found that *MMP9* expression is correlated with glioma grade (p\<0.0001, [Fig 1A](#pone.0151815.g001){ref-type="fig"}) and that low *MMP9* expression is an independent prognostic factor for better survival in primary GBM patients (OS: p = 0.027 and PFS: p = 0.032). In addition, low MMP*9* expression was found to be associated with a good response to temozolomide therapy among other clinicopathologic factors. It may contribute to the reasonable usage of TMZ.

10.1371/journal.pone.0151815.t001

###### The associations of MMPs with overall survival (OS).
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  MMPs          HR       95%CI            p value
  ------------- -------- ---------------- ---------
  ***MMP9***    1.2048   1.0889--1.3331   0.0003
  ***MMP1***    1.1671   1.055--1.291     0.0027
  ***MMP19***   1.2371   1.0463--1.4627   0.0128
  ***MMP7***    1.1012   1.0133--1.1967   0.0231
  ***MMP28***   0.6625   0.4441--0.9883   0.0436
  ***MMP11***   1.1354   1.0006--1.2883   0.0489
  ***MMP22***   1.2494   0.9855--1.5839   0.0659
  ***MMP12***   1.1244   0.9909--1.2759   0.0691
  ***MMP24***   0.7787   0.5731--1.0579   0.1096
  ***MMP14***   1.1153   0.947--1.3134    0.191
  ***MMP10***   1.1044   0.9286--1.3135   0.2616
  ***MMP13***   1.0672   0.9492--1.1998   0.2765
  ***MMP3***    1.0746   0.9313--1.24     0.3243
  ***MMP25***   0.8812   0.6678--1.1627   0.3712
  ***MMP16***   0.9066   0.7282--1.1287   0.3804
  ***MMP21***   0.8585   0.5884--1.2524   0.4283
  ***MMP17***   0.8961   0.6669--1.2041   0.4666
  ***MMP8***    1.0559   0.8497--1.3122   0.6237
  ***MMP2***    0.9599   0.784--1.1753    0.6918
  ***MMP20***   0.9628   0.7784--1.1909   0.727
  ***MMP26***   0.9722   0.7757--1.2184   0.8065
  ***MMP15***   1.0232   0.7209--1.4523   0.8977
  ***MMP27***   1.0045   0.8119--1.2426   0.9674

Abbreviations: MMP: Matrix metalloproteinase; HR: hazard ratio.

![*MMP9* expression was correlated with glioma grade.\
(A) *MMP9* expression was correlated with glioma grade (p\<0.001). Glioma of grade IV showed a significantly increased in *MMP9* expression compared to grade II and III gliomas (p\<0.0001, p\<0.0001, respectively). *MMP9* expression level in grade III gliomas was markedly higher than that in grade II gliomas (p\<0.0001). (B, C) Likelihood ratio test showed that *MMP9* was significantly associated with tumor grade in two independent glioma dataset (p\<0.001, p\<0.001, respectively) \* p\< 0.05; \*\*\*\* p\<0.0001.](pone.0151815.g001){#pone.0151815.g001}

Materials and Methods {#sec006}
=====================

Datasets used in this study {#sec007}
---------------------------

Whole genome mRNA expression microarray data and clinical information of 305 glioma and five normal brain samples from the Chinese Glioma Genome Atlas (CGGA) database\[[@pone.0151815.ref031]\] (<http://www.cgga.org.cn>) were obtained as a testing set, and this dataset contains 126 grade II, 51 grade III and 128 grade IV samples histologically diagnosed according to the 2007 World Health Organization classification of tumors of the central nervous system\[[@pone.0151815.ref032]\]. Seventy-eight primary GBM samples with complete clinical information were included in prognostic analysis. These 78 patients underwent surgical resection and then received standard radiation therapy (RT). Fifty of them received adjuvant temozolomide (TMZ) chemotherapy. Written informed consent was obtained from the patients for the publication of this report. The study was performed with the approval of Ethics Committee of Capital Medical University and Harbin Medical University in compliance with the Helsinki Declaration. We also obtained Gene Expression Profiles of two public datasets as our study validation sets including the Repository for Molecular Brain Neoplasia Data (REMBRANDT, n = 433) and the GSE16011 dataset\[[@pone.0151815.ref033]\] (n = 272). The three datasets were designed as retrospective studies \[[@pone.0151815.ref033]--[@pone.0151815.ref035]\] providing stable and basic tools for glioma research. They are very mature and suitable for glioma investigation, used widely in several teams of glioma research \[[@pone.0151815.ref033]--[@pone.0151815.ref039]\]. GSE16011 dataset \[[@pone.0151815.ref033]\] only has one batch (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011>). Genechips with a glyceraldehyde-3-phosphate dehydrogenase 5′/3′ ratio \>4, present calls \<30%, unsuccessful RT controls, or a background \>200 were excluded. Robustness of sample processing was assessed using eight biological replicates and three technical replicates. Replicates were not included in any analysis. Rembrandt \[[@pone.0151815.ref034]\] contains data generated through the Glioma Molecular Diagnostic Initiative from glioma specimens comprising gene expression arrays, copy number arrays and clinical phenotype data. Data can be queried and visualized for a selected gene across all data platforms or for multiple genes in a selected platform (<https://wiki.nci.nih.gov/display/caIntegrator/caIntegrator+Directory>). The CGGA gene expression profile included two batches. These two batches were both detected by the same array- the Agilent Whole Human Genome Array and the data was normalized. The detailed description was illustrated by the Yan et al's paper \[[@pone.0151815.ref035]\]. Although batch effects can be reduced by careful experimental design, they cannot be eliminated unless the whole study is done in a single batch. Thus, the data have been computationally corrected using methods such as Bayes \[[@pone.0151815.ref040]--[@pone.0151815.ref042]\]. [S1 Table](#pone.0151815.s001){ref-type="supplementary-material"} has illustrated the basic information of the CGGA dataset and the two independent datasets.

Pyrosequencing for *IDH1* Mutation and *MGMT* Promoter Methylation {#sec008}
------------------------------------------------------------------

Genomic DNA was isolated from frozen tissues with a QIAamp DNA Mini Kit (Qiagen) following the manufacturer's protocol. DNA concentration and quality were evaluated with a Nano-Drop ND-1000 spectrophotometer (NanoDrop Technologies, Houston, TX). Pyrosequencing for isocitrate dehydrogenase 1 (*IDH1*) mutations\[[@pone.0151815.ref043]\] and O-6-methylguanine-DNA methyltransferase (*MGMT*) promoter methylation was performed using the PyroMark Q96 ID System (Qiagen, Valencia, Calif)\[[@pone.0151815.ref044]\]. For *IDH1* mutation, the primers `5'-GCTTGTGAGTGGATGGGTAAAAC-3'` and `5'-biotin-TTGCCAACATGACTTACTTGATC-3'` were used for PCR amplification, and the primer `5-TGGATGGGTAAAACCT-3'` was used for pyrosequencing. For *MGMT* promoter methylation, bisulfite modification of the DNA was performed using the EpiTect Kit (Qiagen); the primers `5'-GTTTYGGATATGTTGG GATA-3'` and `5'-biotin-ACCCAAACACTCACCAAATC-3'` were used for PCR, and the primer `5'-GGATATGTTGGGATAGT-3'` was used for pyrosequencing.

Statistical Analysis {#sec009}
--------------------

The prognostic value of all MMP family genes with regards to patient survival was calculated by the Kaplan--Meier method with the two-sided log-rank test (survival) of R, which is an open source statistical software (<https://www.r-project.org/>). The permuted p-value for each gene was corrected by multiple comparison correction using the Benjamini--Hochberg false discovery rate (FDR). Likelihood ratio test was used to test for differences between at least three groups. Differences in clinicopathologic characteristics between the low and high *MMP9* expression groups (designated using the median level of *MMP9* expression as the cutoff value) were evaluated using the chi-square test. Kaplan-Meier survival analysis was used to estimate the survival distributions. The log-rank test in GraphPad Prism, version 4.0 statistical software was used to assess the statistical significance between stratified survival groups. Cox proportional hazard regression analyses were performed using SPSS, version 19.0, software for Windows (SPSS). For all data, the significance level was set at p \< 0.05.

Results {#sec010}
=======

*MMP9* was identified as a prognostic biomarker of primary glioblastoma among MMPs in multiple datasets {#sec011}
-------------------------------------------------------------------------------------------------------

Firstly, the prognostic value of all genes in the MMP family genes in regards to patient survival were calculated for 78 patients with primary GBM from the CGGA dataset. The following MMP members had prognostic value: *MMP9*, *MMP1*, *MMP19*, *MMP7*, *MMP28*, *and MMP11* ([Table 1](#pone.0151815.t001){ref-type="table"}). In addition, we performed multivariate Cox analysis for the MMP members with significant prognostic value in univariate Cox analysis, only the prognostic values of *MMP9* and *MMP11* remained significant. (*MMP9*: [S2 Table](#pone.0151815.s002){ref-type="supplementary-material"}; HR, 1.395; 95%CI, 1.144--1.701; p = 0.001). Although the p value of *MMP11* indicated that it had significant prognostic value, its HR value was not stable (0.76 in the multivariate cox regression analysis and 1.1354 in the univariate cox regression analysis). Then, we investigated the public datasets GSE16011 and Rembrandt and found that *MMP9* was the only MMP that could be confirmed to be associated with survival ([S3 Table](#pone.0151815.s003){ref-type="supplementary-material"}). These results indicated that *MMP9* was a significant prognostic factor among the MMPs.

Correlation of *MMP9* mRNA expression with grade progression {#sec012}
------------------------------------------------------------

The expression level of *MMP9* was analyzed in different grades of glioma (Grade II, n = 126; Grade III, n = 51; and Grade IV, n = 128). *MMP9* expression was correlated with grade progression (p\<0.001, [Fig 1A](#pone.0151815.g001){ref-type="fig"}). As shown in [Fig 1A](#pone.0151815.g001){ref-type="fig"}, *MMP9* expression was significantly increased in grade IV glioma compared to in grade II and III gliomas (p\<0.0001 and p\<0.0001, respectively) and was also markedly higher in grade III glioma than in grade II glioma (p\<0.0001). Next, we employed two independent glioma gene expression dataset (REMBRANDT and GSE16011 datasets) to examine the association between *MMP9* expression level and glioma grade. The results showed that *MMP9* was significantly associated with tumor grade (p\<0.001, [Fig 1B](#pone.0151815.g001){ref-type="fig"}; p\<0.001, [Fig 1C](#pone.0151815.g001){ref-type="fig"}), which was consistent with our results.

*MMP9* is an independent prognostic factor in primary GBM patients {#sec013}
------------------------------------------------------------------

We defined the median level of *MMP9* expression of seventy-eight patients with primary GBM as the cutoff value to divide them into low (n = 39) *MMP9* group and high (n = 39) *MMP9* groups ([Table 2](#pone.0151815.t002){ref-type="table"}). The clinicopathologic features of these two groups are shown in [Table 2](#pone.0151815.t002){ref-type="table"}. The patients in the *MMP9* low expression group were younger and had higher rates of *MGMT* promoter methylation and *IDH1* mutation compared to the patients in the *MMP9* high expression group. Patients with low *MMP9* expression had a longer OS and PFS than patients with high *MMP9* expression (p = 0.0012 and p = 0.0066, respectively; [Fig 2A and 2B](#pone.0151815.g002){ref-type="fig"}). Then two independent datasets (REMBRANDT and GSE16011) were used to validate the association between *MMP9* expression and survival ([Fig 2C and 2D](#pone.0151815.g002){ref-type="fig"}). Consistent with our results, patients with lower *MMP9* expression had improved OS in the two validation datasets (p = 0.0338 and p\<0.0001, respectively). Overall, these results indicated that low *MMP9* is expression of *MMP9* correlated with better survival outcome in primary GBMs.

10.1371/journal.pone.0151815.t002

###### Clinical and molecular pathological features of primary GBM samples in association with *MMP9* expression.
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  Total (n = 78)               Low(n = 39)   High(n = 39)   p value
  ---------------------------- ------------- -------------- ---------
  **Gender**                                                
   Male                        22            24             0.818
   Female                      17            15             
  **Age at diagnosis**                                      
   ≤45                         23            9              0.002
   \>45                        16            30             
  **Preoperative KPS score**                                
   ≥80                         24            19             0.362
   \<80                        15            20             
  ***MGMT***                                                
   Methylated                  20            9              0.017
   Unmethylated                18            29             
   NA                          1             1              
  ***IDH1***                                                
   Mutation                    11            0              \<0.001
   Wild type                   28            39             
  **TMZ chemotherapy**                                      
   Yes                         28            22             0.157
   No                          11            17             
  **Extent of resection**                                   
   Total                       15            12             0.634
   Subtotal                    24            27             

Abbreviations: *IDH1*, isocitrate dehydrogenase 1; KPS, Karnofsky performance scale; *MGMT*, O6-methylguanine-DNA methyltransferase; TMZ, temozolomide. NA, not available. P values were determined using a 2-sided chi-square test of variance.

![Kaplan-Meier plots of progression-free and overall survival duration in patients with primary GBM.\
(A, B) Kaplan--Meier survival analysis of PFS and OS duration in 78 primary GBM patients according to *MMP9* mRNA expression. Patients with low *MMP9* expression had a longer OS and PFS than patients with high *MMP9* expression (p = 0.0012 and p = 0.0066, respectively). (C, D) Two independent datasets (REMBRANDT and GSE16011) were used to validate the association between *MMP9* expression and survival. Patients with lower *MMP9* expression also had improved OS in the two validation datasets (p = 0.0338 and p\<0.0001, respectively).](pone.0151815.g002){#pone.0151815.g002}

We conducted a univariate Cox regression analysis to determine the clinical and genetic variables that were associated with OS for these 78 primary GBM patients ([Table 3](#pone.0151815.t003){ref-type="table"}). *MMP9* expression, preoperative KPS score, age at diagnosis, *MGMT* promoter methylation status and TMZ therapy were statistically associated with OS. We also observed that *MMP9* expression, age at diagnosis and TMZ therapy were statistically associated with PFS. The multivariate Cox regression analysis indicated that *MMP9* expression was an independent prognostic factor for OS and PFS (OS: HR, 1.171; 95% CI, 1.018--1.346; p = 0.027; PFS: HR, 1.146; 95%CI, 1.012--1.299; p = 0.032) ([Table 3](#pone.0151815.t003){ref-type="table"}).

10.1371/journal.pone.0151815.t003

###### Cox Hazard Regression Analysis of the Associations of Clinicopathologic Factors and *MMP9* expression for Survival (n = 78).
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                                    Univariate Cox Regression   Multivariate Cox Regression                                     
  --------------------------------- --------------------------- ----------------------------- ---------- ------- -------------- -------
  ***Overall survival***                                                                                                        
  **Gender**                        0.986                       0.593--1.640                  0.957                             
  **Age at diagnosis**              1.033                       1.011--1.056                  0.004      1.011   0.985--1.038   0.404
  ***MMP9* mRNA expression**        1.248                       1.111--1.403                  \<0.0001   1.171   1.018--1.346   0.027
  **Preoperative KPS score**        0.975                       0.955--0.995                  0.015      0.969   0.948--0.991   0.006
  **TMZ chemotherapy**              2.626                       1.567--4.401                  \<0.0001   2.537   1.407--4.575   0.002
  ***MGMT* promoter methylation**   1.726                       0.999--2.979                  0.05       1.554   0.861--2.802   0.143
  ***IDH1* Mutation status**        2.027                       0.956--4.295                  0.065      1.396   0.590--3.302   0.448
  **Extent of surgery**             1.443                       0.846--2.462                  0.178                             
  ***Progression free survival***                                                                                               
  **Gender**                        0.834                       0.506--1.377                  0.478                             
  **Age at diagnosis**              1.023                       1.002--1.044                  0.029      1.004   0.981--1.028   0.71
  ***MMP9* mRNA expression**        1.2                         1.072--1.343                  0.002      1.146   1.012--1.299   0.032
  **Preoperative KPS score**        0.983                       0.964--1.003                  0.092                             
  **TMZ chemotherapy**              2.628                       1.579--4.375                  \<0.0001   2.2     1.280--3.781   0.004
  ***MGMT* promoter methylation**   1.671                       0.986--2.832                  0.057                             
  ***IDH1* Mutation status**        1.688                       0.829--3.440                  0.149                             
  **Extent of surgery**             1.544                       0.914--2.608                  0.105                             

Abbreviations: KPS, Karnofsky performance status; TMZ: temozolomide; *MGMT*: O6-methylguanine-DNA methyltransferase; *IDH1*: isocitrate dehydrogenase 1; HR: hazard ratio.

Then we also conducted Cox regression analysis to validate the clinical variables and *MMP9* expression in GSE16011 dataset. *MMP9* expression, age at diagnosis were statistically associated with OS (p = 3.08E-9 and p = 6.05E-17, respectively). Because the clinical information of the two datasets was insufficient, we have just used age to adjust in GSE16011 dataset. The multivariate Cox regression analysis indicated that *MMP9* expression was an independent prognostic factor for OS (HR, 2.176; 95% CI, 1.659--2.853; p = 1.94E-8).

Association between *MMP9* expression and the efficacy of temozolomide chemotherapy {#sec014}
-----------------------------------------------------------------------------------

To assess the potential association of *MMP9* with the therapeutic outcome of TMZ treatment, we classified the low *MMP9* and high *MMP9* groups into subgroups according to whether TMZ chemotherapy was received. The Kaplan--Meier survival analysis indicated that patients treated with RT combined with TMZ therapy had better OS and PFS (OS: p = 0.0002; PFS: p = 0.0002) than patients treated with RT alone in the low *MMP9* group ([Fig 3A and 3B](#pone.0151815.g003){ref-type="fig"}). However, in the high *MMP9* group, there was no significant survival benefit of the combination treatment ([Fig 3C and 3D](#pone.0151815.g003){ref-type="fig"}).

![Kaplan-Meier estimates of progression-free and overall survival according to *MMP9* expression and treatment groups.\
(A, B) Kaplan--Meier survival analysis indicated that patients treated with RT combined with TMZ therapy (n = 28) had better OS and PFS (OS: p = 0.0002; PFS: p = 0.0002) than patients with RT alone (n = 11) in low *MMP9* group (n = 39). (C, D) However, in the high *MMP9* group (n = 39), there was no significant survival benefit of the combination treatment (RT alone: n = 17; RT combined TMZ: n = 22).](pone.0151815.g003){#pone.0151815.g003}

It is well known that *MGMT* promoter methylation is related to better survival and that patients with a methylated *MGMT* promoter benefit from TMZ chemotherapy\[[@pone.0151815.ref045]\]. We analyze the correlations of *MGMT* promoter methylation status and *MMP9* expression with TMZ chemotherapy. We divided the low *MMP9* and high *MMP9* groups into subgroups with a methylated and unmethylated *MGMT* promoter. A Kaplan--Meier survival curve analysis with a log-rank comparison was conducted for each subgroup. In the low *MMP9* group, patients who received combined therapy showed improved OS and PFS regardless of *MGMT* methylation status ([Fig 4A, 4B, 4C and 4D](#pone.0151815.g004){ref-type="fig"}). In the high *MMP9* group, TMZ chemotherapy resulted in an improved OS but not an improved PFS in patients with an unmethylated *MGMT* promoter ([Fig 4E and 4F](#pone.0151815.g004){ref-type="fig"}), while TMZ showed no benefit for patients with a methylated *MGMT* promoter ([Fig 4G and 4H](#pone.0151815.g004){ref-type="fig"}). Above results have been validated by cox regression analysis ([S4 Table](#pone.0151815.s004){ref-type="supplementary-material"}). The CGGA and Rembrandt datasets have been uploaded as [S5](#pone.0151815.s005){ref-type="supplementary-material"}, [S6](#pone.0151815.s006){ref-type="supplementary-material"} and [S7](#pone.0151815.s007){ref-type="supplementary-material"} Tables.

![Kaplan-Meier estimates of progression-free and overall survival according to *MMP9* expression, *MGMT* methylation status and treatment groups.\
(A, B, C, D) In the low *MMP9* group, patients who received the combination therapy showed improved OS and PFS regardless of whether the *MGMT* promoter was methylated (n = 20; RT alone: n = 6; RT combined TMZ: n = 14) or unmethylated (n = 18; RT alone: n = 4; RT combined TMZ: n = 14). (E, F, G, H) In the high *MMP9* group, TMZ chemotherapy resulted in better OS but not better PFS in patients with an unmethylated *MGMT* promoter (n = 29; RT alone: n = 12; RT combined TMZ: n = 17), while TMZ did not benefit patients with a methylated *MGMT* promoter (n = 9; RT alone: n = 4; RT combined TMZ: n = 5).](pone.0151815.g004){#pone.0151815.g004}

Discussion {#sec015}
==========

Glioblastoma is the most common malignant primary brain tumor in adults. Despite improved surgery and chemo-radiotherapy approaches, the clinical prognosis for patients with GBM remains dismal\[[@pone.0151815.ref002]\]. The median survival of patients with primary GBM is approximately 1 year, but it varies remarkably from less than few weeks to more than 3 years after diagnosis\[[@pone.0151815.ref046]\], suggesting the limitations of the current clinicopathologic determinants of prognosis and the choice of therapeutic strategies. Thus, it is of great importance to identify more effective biomarkers that can predict clinical outcomes and therapeutic responses to drugs.

Our paper aimed to identify the prognostic and predictive value of MMPs in patients with primary GBM. Several MMPs have been reported to be related with poor prognosis in a large variety of human cancers \[[@pone.0151815.ref017]--[@pone.0151815.ref019]\]. In particular, the over-expression of certain MMPs in high-grade gliomas appear to be correlated with tumor invasiveness and to be prognostically significant \[[@pone.0151815.ref047]\]. MMPs enhance tumor cell invasion by degrading extracellular-matrix proteins, activating signal-transduction cascades that promote motility and solubilizing ECM-bound growth factors\[[@pone.0151815.ref048]\]. Christopher M. Overall and co-workers introduced the use of proteolytic signature peptides (PSPs) in combination with isobaric tags for the proteomic analysis of MMP proteolytic activity\[[@pone.0151815.ref049]\]. The association between kep, a perfusion index, and *MMP9* expression has been demonstrated, and kep can be used as an imaging biomarker of GBM progression and its prognostication \[[@pone.0151815.ref050]\]. In addition, MMPs can cleave and activate other growth factors that are implicated in GBM motility and proliferation, such as TGFβ\[[@pone.0151815.ref051]\]. In our study, we comparatively analyzed the MMP family members based on whole-gene expression profiling from multiple databases, and confirmed that *MMP9* expression was correlated with glioma grade and that low *MMP9* expression was an independent prognostic factor for better survival in primary GBM patients.

Previous studies have performed experiments to examine the mechanism through which *MMP9* affectes the survival of the glioma patients. *MMP9* is known to play an important role in cell migration and invasion in both physiological and pathological processes of gliomagenesis\[[@pone.0151815.ref052]\]. Hu et. al. demonstrated that *MMP9* is predominantly expressed by glioma-associated microglia/macrophages in mouse and human glioma tissue not by glioma cells, and glioma-associated microglial *MMP9* expression is upregulated by TLR2 signaling and is sensitive to minocycline\[[@pone.0151815.ref053]\]. Tie2-expressing monocytes/macrophages are a major source of *MMP9* secretion and activity. After 6 weeks of anti-VEGF therapy, *MMP9* immunostaining of brain tissue sections revealed *MMP9*+ cells at the tumor edge and peripheral invasive tumor nodules with rod or amoeboid shapes characteristic of "activated" microglia/macrophages, and these types of cells were scarcely observed in the control animals\[[@pone.0151815.ref054]\]. Our team previously used miRNA microarrays to identify the *MMP9*-specific miRNA expression profile of GBM. which may be used to determine potential targets of anti-invasion therapy for GBM \[[@pone.0151815.ref055]\]. Serum *MMP9* level was determined by ELISA and was found to be correlated with radiographic status and survival \[[@pone.0151815.ref056]\]. *MMP9* silencing decreased oncogenic c-Myc expression and induced senescence and apoptosis in glioma cells by inhibiting hTERT expression and telomere activity \[[@pone.0151815.ref057]\]. *MMP9* was also found to be involved in EGFR/Ras/MEK and PI3K/AKT signaling pathway-mediated cell invasion and anchorage-independent growth in U1242 MG cells \[[@pone.0151815.ref058]\]. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced *MMP9* expression in human astrocytoma cells through activation of extracellular signal-regulated protein kinase (ERK). In addition, TRAIL induced the DNA-binding activity of NF-κB, an important transcription factor for *MMP9* induction\[[@pone.0151815.ref059]\]. These experiments demonstrated that *MMP9* directly impacts the survival of glioma patients.

Radiation therapy plus TMZ chemotherapy as the first-line treatment for GBM has extended the survival of GBM patients. However, the survival benefit and response to TMZ is variable among patients. The critical reason for the poor prognosis of primary GBM is therapeutic resistance, especially TMZ-resistance, which eventually results in tumor recurrence\[[@pone.0151815.ref060]\]. It is unclear whether *MMP9* influences the response to TMZ in primary GBM patients. Our data showed an association between *MMP9* expression and the efficacy of temozolomide chemotherapy. TMZ produces the mono-functional DNA adducts O^6^-MeG and N^7^-MeG adducts, and the former is considered a lethal DNA lesion\[[@pone.0151815.ref061]\]. A report published in *Oncotarget* demonstrated that miR-211 or shRNA-specific for *MMP9* in combination with ionizing radiation and temozolomide significantly induced apoptosis and DNA fragmentation. Additionally, that report showed that glioma stem cells treated with miR-211- and shRNA-specific for *MMP9* (pM) had increased drug retention capacity. \[[@pone.0151815.ref047]\] These mechanisms may explain why GBM patients with low *MMP9* expression have a better response to TMZ chemotherapy. It is well known that patients with methylation of *MGMT* promoter benefit from TMZ chemotherapy \[[@pone.0151815.ref062]\]. Therefore, we analyzed the correlations of *MGMT* methylation status and *MMP9* expression with TMZ chemotherapy efficacy. TMZ benefited patients with low *MMP9* expression whether the *MGMT* promoter was methylated or unmethylated. This greatly supports the predictive value of *MMP9* for the response to TMZ. On the other hand, in the high *MMP9* group, TMZ chemotherapy resulted in better OS but not better PFS in patients with an unmethylated *MGMT* promoter, and TMZ did not benefit the patients with a methylated *MGMT* promoter.

In conclusion, we confirmed the association between *MMP9* expression and giloma grade, and highlighted the prognostic and predictive value of *MMP9* among all MMP family members in primary GBMs. These findings suggest that *MMP9* is a potential prognostic and predictive biomarker for glioma and can be used to establish more personalized therapeutic strategies. The US clinical trial "*MMP2*, *MMP9* and *NGAL* as Biomarkers for Glioblastoma (GBM) Biomarkers for the Prognosis of Glioblastoma (NCT01493219)" has been sponsored by University of Nebraska started since 2011. In the future, more work should focus on in-depth molecular mechanisms to provide a more comprehensive understanding of the roles of MMPs in GBM.
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